Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?

HLX43 and HLX3902 milestones put Shanghai Henlius Biotech’s pipeline in focus

Shanghai Henlius Biotech (SEHK:2696) has reported fresh progress in its oncology pipeline. Regulators in China cleared a new HLX43 clinical trial in advanced solid tumours, and the first patient received HLX3902 in an early prostate cancer study.

See our latest analysis for Shanghai Henlius Biotech.

Shanghai Henlius Biotech’s recent HLX43 and HLX3902 updates have arrived alongside a sharp shift in sentiment, with the share price at HK$66.95 after a 20.31% 7 day share price return and a 14.25% year to date share price return. However, the 1 year total shareholder return has declined 9.83%, while the very large 3 year total shareholder return and a more than doubling over 5 years highlight how strong earlier momentum now looks more mixed.

If oncology news like this has your attention, it may be a good time to widen your watchlist and scan for other high potential healthcare AI opportunities using our stock screener, starting with 130 healthcare AI stocks

Shanghai Henlius Biotech now trades at a large discount to both analyst targets and intrinsic estimates after a strong recent move. The key question is whether the market is being sensibly cautious about execution risk, or too slow to reprice the pipeline progress.

Price to earnings for Shanghai Henlius Biotech, is the premium justified?

On the latest figures, Shanghai Henlius Biotech trades on a P/E of 37.8x, which is higher than both the Asian Biotechs industry average of 31.4x and the peer average of 36.8x. The market is paying a clear premium for each dollar of current earnings compared with sector and peer benchmarks.

The P/E ratio compares the HK$66.95 share price with the company’s earnings per share. For a biotech such as Shanghai Henlius Biotech, this is a common way investors gauge how much of today’s price reflects expectations for future profit growth. A higher P/E usually signals that the market is factoring in stronger earnings or a higher quality earnings profile.

Here, the current P/E sits meaningfully above both the industry and the peer averages, while the estimated fair P/E ratio is 19.1x. That gap implies the present market price builds in richer expectations than the level the fair ratio points to, and it highlights how far sentiment could shift if expectations and reality move closer together.

Explore the SWS fair ratio for Shanghai Henlius Biotech

Result: Price-to-earnings of 37.8x (OVERVALUED)

However, Shanghai Henlius Biotech still faces clinical and regulatory hurdles across its broad pipeline, and any setbacks could quickly cool the recent share price momentum.

Find out about the key risks to this Shanghai Henlius Biotech narrative.

Another view on Shanghai Henlius Biotech’s valuation

The P/E premium makes Shanghai Henlius Biotech look expensive, yet our DCF model points the other way. At HK$66.95, the stock trades about 64% below an estimated cash flow value of HK$185.86. One model flags risk of overpaying on earnings; the other suggests a sizeable discount. Which signal feels more compelling to you?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shanghai Henlius Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 263 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With the mixed signals around Shanghai Henlius Biotech’s valuation and pipeline, it helps to see the full picture on risks and rewards yourself. Take a closer look at the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Shanghai Henlius Biotech?

If Shanghai Henlius Biotech has sharpened your focus, do not stop there. Broaden your opportunity set with other stocks that fit clear, disciplined criteria using the Simply Wall St screener.

• Target stability first and cut down portfolio surprises by using the 298 resilient stocks with low risk scores.
• Hunt for quality at a compelling price by running the 263 high quality undervalued stocks.
• Spot companies that quietly compound with strong finances through the solid balance sheet and fundamentals stocks screener (423 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com